The Role of Steroid Hormone Receptors in Urothelial Tumorigenesis.

androgen receptor estrogen receptor glucocorticoid receptor progesterone receptor urothelial cancer vitamin D receptor

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
04 Aug 2020
Historique:
received: 07 07 2020
revised: 28 07 2020
accepted: 01 08 2020
entrez: 8 8 2020
pubmed: 8 8 2020
medline: 8 8 2020
Statut: epublish

Résumé

Preclinical and/or clinical evidence has indicated a potential role of steroid hormone-mediated signaling pathways in the development of various neoplastic diseases, while precise mechanisms for the functions of specific receptors remain poorly understood. Specifically, in urothelial cancer where sex-related differences particularly in its incidence are noted, activation of sex hormone receptors, such as androgen receptor and estrogen receptor-β, has been associated with the induction of tumor development. More recently, glucocorticoid receptor has been implied to function as a suppressor of urothelial tumorigenesis. This article summarizes and discusses available data suggesting that steroid hormone receptors, including androgen receptor, estrogen receptor-α, estrogen receptor-β, glucocorticoid receptor, progesterone receptor and vitamin D receptor, as well as their related signals, contribute to modulating urothelial tumorigenesis.

Identifiants

pubmed: 32759680
pii: cancers12082155
doi: 10.3390/cancers12082155
pmc: PMC7465876
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Oncol Rep. 2010 Mar;23(3):811-8
pubmed: 20127024
Transl Oncol. 2017 Jun;10(3):340-345
pubmed: 28342317
Am J Surg Pathol. 2014 Aug;38(8):e20-34
pubmed: 25029121
Urol Res. 1975 Aug 8;3(2):73-9
pubmed: 1162802
Am J Cancer Res. 2015 Sep 15;5(10):2959-68
pubmed: 26693052
Am J Transl Res. 2020 May 15;12(5):1779-1788
pubmed: 32509176
Eur Urol. 2005 Jan;47(1):52-7
pubmed: 15582249
Int J Cancer. 2015 Feb 15;136(4):E27-38
pubmed: 25138562
J Urol. 2001 Jan;165(1):253-8
pubmed: 11125420
Endocr Connect. 2018 Dec 1;7(12):1397-1408
pubmed: 30521479
J Biomed Sci. 2008 Mar;15(2):261-9
pubmed: 17922225
Int J Urol. 2010 Sep;17(9):801-9
pubmed: 20727050
Oncotarget. 2015 Jan 20;6(2):836-45
pubmed: 25596734
Am J Clin Pathol. 2014 Aug;142(2):157-64
pubmed: 25015855
Maturitas. 2010 Dec;67(4):353-7
pubmed: 20813471
Endocr Relat Cancer. 2013 May 20;20(3):293-304
pubmed: 23447569
Mol Carcinog. 2011 Dec;50(12):931-44
pubmed: 21400613
Am J Cancer Res. 2014 Sep 06;4(5):461-73
pubmed: 25232488
Histopathology. 1997 Jun;30(6):556-62
pubmed: 9205860
Cancer Res. 2013 Oct 1;73(19):5914-25
pubmed: 23928991
Cancer Res. 2016 Sep 1;76(17):5175-85
pubmed: 27312530
BMC Cancer. 2019 Apr 8;19(1):331
pubmed: 30961575
Am J Cancer Res. 2018 Nov 01;8(11):2325-2336
pubmed: 30555747
Int J Mol Sci. 2018 Mar 08;19(3):
pubmed: 29518027
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2786-94
pubmed: 18843024
Oncotarget. 2016 Mar 22;7(12):14153-60
pubmed: 26885620
Br J Cancer. 2018 Oct;119(8):961-970
pubmed: 30327565
Mol Carcinog. 2014 Apr;53(4):314-24
pubmed: 23143693
Am J Pathol. 2009 Aug;175(2):489-99
pubmed: 19628766
Urol Oncol. 2019 Jun;37(6):353.e9-353.e15
pubmed: 30737158
Mol Cancer Ther. 2018 Jun;17(6):1303-1314
pubmed: 29592878
Urol J. 2014 Nov 30;11(6):1968-73
pubmed: 25433476
Endocr Relat Cancer. 2020 Feb 1;:
pubmed: 32031965
BJU Int. 2007 Apr;99(4):933-7
pubmed: 17378851
BJU Int. 2012 Jun;109(11):1716-26
pubmed: 22221549
Cancer. 2006 Jun 15;106(12):2610-6
pubmed: 16700038
Oncotarget. 2015 Jun 10;6(16):14710-9
pubmed: 25900243
Hum Pathol. 2012 Nov;43(11):2033-40
pubmed: 22607700
Int J Urol. 2019 Feb;26(2):305-306
pubmed: 30378192
J Urol. 2002 Nov;168(5):2220-6
pubmed: 12394763
Oncotarget. 2014 Sep 15;5(17):7917-35
pubmed: 25277204
Transl Oncol. 2013 Jun 01;6(3):244-55
pubmed: 23730403
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
Endocr Relat Cancer. 2008 Mar;15(1):351-64
pubmed: 18310301
Mol Endocrinol. 2015 Oct;29(10):1486-97
pubmed: 26322830
Mol Carcinog. 2013 Feb;52(2):94-102
pubmed: 22086872
Eur Urol. 1997;31(3):360-4
pubmed: 9129932
Oncol Lett. 2019 Jan;17(1):482-487
pubmed: 30655790
Int J Clin Exp Pathol. 2015 Sep 01;8(9):10283-93
pubmed: 26617736
J Urol. 2017 Feb;197(2):308-313
pubmed: 27506696
PLoS One. 2016 Feb 10;11(2):e0148851
pubmed: 26862755
Hum Pathol. 2017 Jun;64:83-90
pubmed: 28428106
Cancer Biol Ther. 2016 Nov;17(11):1188-1196
pubmed: 27635763
J Biol Chem. 1999 Sep 24;274(39):27857-66
pubmed: 10488132
Br J Cancer. 2009 Oct 20;101(8):1316-20
pubmed: 19773763
Eur J Pharmacol. 2004 Oct 1;500(1-3):51-62
pubmed: 15464020
Cancer Res. 1984 Oct;44(10):4560-73
pubmed: 6467211
Int J Urol. 2018 May;25(5):429-435
pubmed: 29444544
Oncotarget. 2014 Dec 30;5(24):12665-74
pubmed: 25557268
Int J Cancer. 2007 Sep 1;121(5):999-1008
pubmed: 17487836
Urol Oncol. 2011 Jan-Feb;29(1):43-51
pubmed: 19372057
Am J Cancer Res. 2017 Oct 01;7(10):2041-2050
pubmed: 29119053
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Res. 2006 Feb 1;66(3):1337-45
pubmed: 16452187
Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3588-96
pubmed: 23012401
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Mol Sci. 2015 Oct 15;16(10):24369-86
pubmed: 26501255
PLoS One. 2017 Mar 31;12(3):e0174746
pubmed: 28362839
Tumour Biol. 2015 Mar;36(3):1567-72
pubmed: 25359617
Am J Pathol. 2013 May;182(5):1811-20
pubmed: 23499463
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518063
Mol Cell Endocrinol. 2003 Mar 28;201(1-2):155-64
pubmed: 12706303
Carcinogenesis. 2014 Mar;35(3):651-61
pubmed: 24148819
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):11-21
pubmed: 17070034
Urology. 2004 Aug;64(2):383-8
pubmed: 15302512
Oncotarget. 2015 Oct 6;6(30):29860-76
pubmed: 26342199
Urology. 2008 Sep;72(3):470-3
pubmed: 18533230
Oncol Lett. 2013 Jul;6(1):96-100
pubmed: 23946784
Oncol Lett. 2018 Jun;15(6):8417-8423
pubmed: 29805577
Tumour Biol. 2012 Apr;33(2):347-61
pubmed: 22274923
Mol Carcinog. 2019 Dec;58(12):2297-2305
pubmed: 31535408
J Natl Cancer Inst. 2007 Apr 4;99(7):558-68
pubmed: 17406000

Auteurs

Hiroki Ide (H)

Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Hiroshi Miyamoto (H)

Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.
James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.

Classifications MeSH